Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
New targets for myeloma-related bone disease
Paediatric treatment regimens for acute lymphoblastic leukaemia in adolescents and young adults
The success of Phase III TOWER trial of blinatumomab in ALL